ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	978.38	883.37	614.38	486.82	316.39	216.14
Revenue Growth	30.90%	43.78%	26.20%	53.87%	46.38%	3.67%
Gross Profit Gross Profit Growth	590.98	542.06	377.77	305.3	177.6	115.53
Operating Income Operating Income Growth	123.6	83.33	33.92	49.53	-25.73	-28.17
Net Income Net Income Growth	99.6	70.22	-20.15	15.48	-49.52	-42.79
Earnings Per Share EPS Growth	4.54	3.32	-1.04	0.85	-3.05	-3.40
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Generics and Other Generics and Other Growth	412.06	399.43	320.03	289.31	235.24
Rare Disease and Brands Rare Disease and Brands Growth	566.32	483.93	294.34	197.5	81.15
Total Total Growth	978.38	883.37	614.38	486.82	316.39

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	376.96	294.72	151.17	221.12	48.23	100.3
Total Debt Total Debt Growth	626.03	628.28	624.09	285.67	287.9	287.37
Net Cash (Debt) Net Cash Growth	-249.07	-333.57	-472.92	-64.55	-239.67	-187.07
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-11.30	-15.71	-24.48	-3.55	-14.74	-14.85

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	189.47	185.23	64.02	118.96	-31.2	3.32
Capital Expenditures CapEx Growth	-16.48	-13.84	-16.24	-8.87	-8.88	-2.56
Free Cash Flow Free Cash Flow Growth	172.99	171.39	47.78	110.09	-40.08	0.77
Free Cash Flow Growth	37.90%	258.70%	-56.60%	-	-	-91.62%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	60.40%	61.36%	61.49%	62.71%	56.13%	53.45%
Operating Margin	12.63%	9.43%	5.52%	10.17%	-8.13%	-13.03%
Pretax Margin	14.57%	10.84%	-3.62%	4.08%	-19.81%	-25.94%
Profit Margin	10.18%	7.95%	-3.28%	3.18%	-15.65%	-19.80%
FCF Margin	17.68%	19.40%	7.78%	22.61%	-12.67%	0.35%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	16.04	23.50	-	68.00	-	-
Forward PE	7.74	10.03	10.72	14.04	14.79	12.86
P/FCF Ratio	9.02	9.63	22.59	9.56	-	1008.43
PS Ratio	1.60	1.87	1.76	2.16	2.07	3.57

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error